Ubs Group Ag Lantern Pharma Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Lantern Pharma Inc. stock. As of the latest transaction made, Ubs Group Ag holds 26,871 shares of LTRN stock, worth $91,898. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,871

Previous 25,500 5.38%

Holding current value

$91,898

Previous $119,000 17.65%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.42 - $4.83 $4,688 - $6,621	1,371 Added 5.38%	26,871 $98,000
Q1 2024 May 13, 2024	SELL	$3.73 - $10.65 $1,708 - $4,877	-458 Reduced 1.76%	25,500 $224,000
Q4 2023 Feb 09, 2024	SELL	$2.48 - $4.39 $2,584 - $4,574	-1,042 Reduced 3.86%	25,958 $111,000
Q1 2023 May 12, 2023	BUY	$4.3 - $6.2 $52,283 - $75,385	12,159 Added 81.93%	27,000 $130,000
Q4 2022 Feb 08, 2023	BUY	$4.19 - $6.04 $11,903 - $17,159	2,841 Added 23.67%	14,841 $89,000
Q3 2022 Nov 10, 2022	SELL	$4.59 - $6.5 $229 - $325	-50 Reduced 0.41%	12,000 $57,000
Q2 2022 Aug 10, 2022	SELL	$4.82 - $7.45 $9,090 - $14,050	-1,886 Reduced 13.53%	12,050 $69,000
Q1 2022 May 16, 2022	BUY	$5.6 - $8.22 $4,625 - $6,789	826 Added 6.3%	13,936 $100,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $11.04 $38,628 - $59,980	5,433 Added 70.77%	13,110 $105,000
Q3 2021 Nov 15, 2021	SELL	$10.53 - $14.93 $5,970 - $8,465	-567 Reduced 6.88%	7,677 $86,000
Q2 2021 Aug 13, 2021	BUY	$12.94 - $19.89 $78,649 - $120,891	6,078 Added 280.61%	8,244 $121,000
Q1 2021 May 12, 2021	BUY	$14.34 - $21.92 $31,060 - $47,478	2,166 New	2,166 $39,000
Q4 2020 Feb 11, 2021	SELL	$15.1 - $20.69 $1,691 - $2,317	-112 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$10.7 - $21.25 $15,204 - $30,196	-1,421 Reduced 92.69%	112 $2,000
Q2 2020 Jul 31, 2020	BUY	$11.54 - $14.95 $17,690 - $22,918	1,533 New	1,533 $19,000

Others Institutions Holding LTRN

# of Institutions

Shares Held

1.31M

Call Options Held

39.8K

Put Options Held

6.1K

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $37M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account